Organon stock sits 17.15 percent above USD 11.40 consensus target

Published on 10/17/2026 at 21:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Third-quarter results are estimated for November 9, 2026, with revenue of USD 1.58 billion. Organon stock was last at EUR 12.26 on October 16, 2026.

Key investor markers

On October 13, 2026, seven brokerages carried a Reduce consensus and a USD 11.40 average target.
MarketBeat estimated USD 1.58 billion in third-quarter revenue on October 16, 2026.
Organon stock was last at EUR 12.26 at Lang & Schwarz on October 16, 2026 at 11:00 p.m. CEST.
Organon had a 17.87 P/E ratio and a 0.60 percent dividend yield.

OGN, US68622V1061, Illustration mit AI erstellt.

Seven brokerages carried a Reduce consensus on Organon & Co. on October 13, 2026, with an average 12-month target of USD 11.40. Against the USD 13.76 closing price on October 16, that target stood 17.15 percent below the stock price, according to MarketBeat. The contrast gives the upcoming results added importance.

Revenue points to November

MarketBeat estimated third-quarter 2026 revenue at USD 1.58 billion and earnings per share at USD 0.88, compared with USD 1.60 billion and USD 1.01 in the year-earlier quarter. The estimates imply revenue growth of minus 1.60 percent and earnings-per-share growth of minus 12.90 percent on the same year-over-year basis.

Price position on October 16

Organon operates in healthcare, with businesses in women's health, biosimilars and established medicines. On October 16, 2026, its U.S. closing price was USD 13.76, while the 52-week range ran from USD 5.69 to USD 13.83. The closing level was 0.51 percent below the yearly high.

On October 16, 2026, Organon had a market capitalization of USD 3.6 billion and a P/E ratio of 17.87. MarketBeat reported a quarterly dividend of USD 0.02 per share and a dividend yield of 0.60 percent on October 13, 2026. The company is listed on the NYSE under ticker OGN.

Valuation and next date

The next scheduled reporting date is November 9, 2026, according to MarketBeat. Its estimates give investors a concrete checkpoint for testing the USD 11.40 consensus target against revenue and earnings delivery.

Comparison with peers

Organon (NYSE, USD): P/E 17.87, market capitalization USD 3.6 billion.

Merck & Co. (NYSE, USD): P/E 116.77, market capitalization USD 360.1 billion.

Viatris (Nasdaq, USD): P/E minus 51.82, market capitalization USD 21.4 billion.

Last euro quotation

The last euro quotation stood at EUR 12.26 at Lang & Schwarz on October 16, 2026 at 11:00 p.m. CEST. The U.S. market was closed on October 17, 2026, so the dated quotation provides the latest euro market level for German investors.

The further course of trading is shown by the continuously updated real-time quote of Organon stock.